KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) Leases (2019 - 2025)

Amneal Pharmaceuticals (AMRX) has 7 years of Leases data on record, last reported at $54.0 million in Q4 2025.

  • For Q4 2025, Leases rose 27.62% year-over-year to $54.0 million; the TTM value through Dec 2025 reached $54.0 million, up 27.62%, while the annual FY2025 figure was $54.0 million, 27.62% up from the prior year.
  • Leases reached $54.0 million in Q4 2025 per AMRX's latest filing, up from $16.9 million in the prior quarter.
  • Across five years, Leases topped out at $66.8 million in Q2 2021 and bottomed at $16.9 million in Q3 2025.
  • Average Leases over 5 years is $40.6 million, with a median of $36.5 million recorded in 2022.
  • Peak YoY movement for Leases: surged 155.04% in 2021, then tumbled 48.66% in 2025.
  • A 5-year view of Leases shows it stood at $60.4 million in 2021, then dropped by 7.04% to $56.1 million in 2022, then fell by 22.88% to $43.3 million in 2023, then decreased by 2.15% to $42.4 million in 2024, then grew by 27.62% to $54.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $54.0 million in Q4 2025, $16.9 million in Q3 2025, and $33.2 million in Q2 2025.